Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome | Synapse
January 14, 2026
Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome
Key Points
The study aims to assess the concordance between biological and clinical staging of Alzheimer disease in individuals with Down syndrome.
Cross-sectional study design
Data from Alzheimer Biomarker Consortium–Down Syndrome study
Participants with Down syndrome examined for Alzheimer disease staging
Clinical and biological Alzheimer disease staging shows concordance
Identified biomarkers associated with disease progression in down syndrome
Abstract
This cross-sectional study examines data for participants in the Alzheimer Biomarker Consortium–Down Syndrome study to gauge the concordance of clinical and biological Alzheimer disease staging.